Podcasts about AUC

Pays démocratique et républicain, la France nourrit un paradoxe : dans la mémoire collective des Français, la figure de l'homme providentiel a une place de choix. Parmi ces hommes et femmes surgissant dans des circonstances souvent exceptionnelles, se trouve Charles De Gaulle. Incarnation de la France libre pendant la Seconde Guerre mondiale, instigateur de la Ve République en 1958, le Général de Gaulle a, par deux fois, fait figure de sauveur dans notre pays. Comment s'est construit le mythe gaullien de l'homme providentiel ? Pour répondre à cette question, Virginie Girod reçoit l'historien Jean Garrigues. Fin connaisseur de l'histoire de nos institutions, il est président de la commission internationale d'histoire des assemblées, et auteur, notamment, des livres "A la plage avec Charles de Gaulle, l'homme providentiel dans un transat" (Dunod) et "Les Hommes providentiels: Histoire d'une fascination française" (Payot).Au Cœur de l'Histoire est un podcast Europe 1.Présentation : Virginie GirodProduction : Armelle ThibergeRéalisation : Clément IbrahimDiffusion : Estelle LafontComposition du générique : Julien TharaudVisuel : Sidonie ManginHébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

  Au Cœur de l'Histoire est un podcast Europe 1. - Présentation et écriture : Virginie Girod - Production : Armelle Thiberge - Réalisation : Nicolas Gaspard - Diffusion : Estelle Lafont - Composition du générique : Julien Tharaud - Promotion et coordination des partenariats : Marie Corpet - Visuel : Sidonie Mangin   Des heures et des heures d'Au Coeur de l'Histoire à écouter ! Découvrez  Au Coeur de l'Histoire +, une nouvelle offre pour accéder en avant-première aux nouveaux épisodes et en exclusivité à nos meilleures archives sur Versailles ou Napoléon par exemple. L'abonnement Au Coeur de l'Histoire + est disponible sur Apple Podcasts en cliquant ici                           Comment s'abonner ? Où écouter ? Quels sont les avantages d'Au Cœur de l'Histoire + ? Le mode d'emploi est disponible ici.   Vous voulez écouter les autres épisodes d'Au Cœur de l'Histoire ? >> Retrouvez-les sur notre site Europe1.fr et sur Apple Podcasts, Spotify, Deezer, Amazon Music, Dailymotion et YouTube, ou vos plateformes habituelles d'écoute. >> Retrouvez ici le mode d'emploi pour écouter tous les podcasts d'Europe 1     Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Virginie Girod raconte Condorcet (1743-1794), homme du XVIIIe siècle et figure oubliée des Lumières sacrifiée par la Révolution. Dans le premier épisode de ce double récit inédit d'Au coeur de l'Histoire, Nicolas de Caritat, marquis de Condorcet, porte les idées des Lumières. Formé à Paris, proche des encyclopédistes, il prend fait et cause pour les droits de l'homme, défendant des idées modernes telles la fin de l'escalavage et l'émancipation des femmes. En 1789, Condorcet prend part à la Révolution française. Au Cœur de l'Histoire est un podcast Europe 1.Présentation et écriture : Virginie GirodProduction : Armelle ThibergeRéalisation : Nicolas GaspardDiffusion : Estelle LafontComposition du générique : Julien TharaudVisuel : Sidonie ManginHébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Stéphane Bern raconte Jules Ferry, nommé ministre de l'Instruction publique en février 1879, qui a révolutionné l'école, en la rendant laïque, gratuite et obligatoire, et consolidé la République par ses lois historiques. Dans quel contexte les lois relatives à l'école portées par Jules Ferry sont-elles promulguées ? Quelles autres lois fondatrices de notre République lui doit-on ? Pourquoi cette figure de la IIIᵉ République suscite-t-elle la controverse ? Pour en parler, Stéphane Bern reçoit Paul Baquiast et Bertrand Sabot, historiens, auteurs de la biographie "Jules Ferry" (Editions Ellipses). Au Cœur de l'Histoire est réalisée par Guillaume Vasseau. Rédaction en chef : Benjamin Delsol. Auteur du récit : Simon Veille. Journaliste : Armelle Thiberge.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Stéphane Bern raconte Jules Ferry, nommé ministre de l'Instruction publique en février 1879, qui a révolutionné l'école, en la rendant laïque, gratuite et obligatoire, et consolidé la République par ses lois historiques. Dans quel contexte les lois relatives à l'école portées par Jules Ferry sont-elles promulguées ? Quelles autres lois fondatrices de notre République lui doit-on ? Pourquoi cette figure de la IIIᵉ République suscite-t-elle la controverse ? Pour en parler, Stéphane Bern reçoit Paul Baquiast et Bertrand Sabot, historiens, auteurs de la biographie "Jules Ferry" (Editions Ellipses). Au Cœur de l'Histoire est réalisée par Guillaume Vasseau. Rédaction en chef : Benjamin Delsol. Auteur du récit : Simon Veille. Journaliste : Armelle Thiberge.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Stéphane Bern nous convie à un voyage... en bateau, à bord du France, le plus grand paquebot jamais construit lors de sa mise à l'eau, il y a 65 ans presque jour pour jour, un "bateau gigantesque" comme le chantait Michel Sardou, qui a tristement fini en cale sèche… Qu'incarne le paquebot France dans notre imaginaire collectif ? Quels sont les enjeux de sa construction ? En quoi est-il l'ambassadeur de la France sur les mers ? Pour en parler, Stéphane Bern reçoit Gabriel Courgeon, chargé des collections du Musée national de la Marine de Paris. Au Cœur de l'Histoire est réalisée par Guillaume Vasseau. Rédaction en chef : Benjamin Delsol. Auteur du récit : Jean-Christophe Piot. Journaliste : Clara Leger.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Stéphane Bern nous convie à un voyage... en bateau, à bord du France, le plus grand paquebot jamais construit lors de sa mise à l'eau, il y a 65 ans presque jour pour jour, un "bateau gigantesque" comme le chantait Michel Sardou, qui a tristement fini en cale sèche… Qu'incarne le paquebot France dans notre imaginaire collectif ? Quels sont les enjeux de sa construction ? En quoi est-il l'ambassadeur de la France sur les mers ? Pour en parler, Stéphane Bern reçoit Gabriel Courgeon, chargé des collections du Musée national de la Marine de Paris. Au Cœur de l'Histoire est réalisée par Guillaume Vasseau. Rédaction en chef : Benjamin Delsol. Auteur du récit : Jean-Christophe Piot. Journaliste : Clara Leger.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

En este episodio de Paredro Podcast conversamos con Alfredo Garzón y Verónica Ochoa, autores de Garzón. El duelo imposible, una novela gráfica profundamente conmovedora que parte del duelo personal y termina siendo un retrato colectivo del país.A 26 años del asesinato de Jaime Garzón —y en medio de un nuevo clima de violencia política en Colombia— este libro nos recuerda por qué la palabra, el humor y la memoria siguen siendo herramientas de resistencia.Jaime Garzón Forero fue abogado, periodista, humorista y mediador humanitario. Usó la sátira para denunciar los abusos del poder y trabajó incansablemente por la paz. Fue asesinado el 13 de agosto de 1999 por sicarios de las AUC, con complicidad de sectores del Estado. Tenía 38 años.Este episodio es una invitación a recordarlo desde el arte, la conversación y la esperanza.

Stéphane Bern raconte, en ce vendredi, non pas le dernier repas du Christ avec ses apôtres, mais la célébrissime peinture que le génie Léonard de Vinci, aussi imprévisible qu'insaisissable, en a fait : la Cène, l'immense chef-d'œuvre de la Renaissance et l'une des œuvres d'art les plus mythiques – et mystiques – de tous les temps… En quoi la vision de La Cène de Léonard de Vinci est-elle complètement nouvelle ? Comment a-t-il réussi à rendre “vivante” son œuvre ? Comment expliquer qu'autant d'énigmes continuent de l'entourer ? Pour en parler, Stéphane Bern reçoit Vincent Delieuvin, conservateur en chef chargé de la peinture italienne du 16ᵉ siècle au Musée du Louvre. Au Cœur de l'Histoire est réalisée par Pierre Cazalot. Rédaction en chef : Benjamin Delsol. Auteur du récit : Eloi Audoin-Rouzeau. Journaliste : Clara Leger.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Stéphane Bern raconte, en ce vendredi, non pas le dernier repas du Christ avec ses apôtres, mais la célébrissime peinture que le génie Léonard de Vinci, aussi imprévisible qu'insaisissable, en a fait : la Cène, l'immense chef-d'œuvre de la Renaissance et l'une des œuvres d'art les plus mythiques – et mystiques – de tous les temps… En quoi la vision de La Cène de Léonard de Vinci est-elle complètement nouvelle ? Comment a-t-il réussi à rendre “vivante” son œuvre ? Comment expliquer qu'autant d'énigmes continuent de l'entourer ? Pour en parler, Stéphane Bern reçoit Vincent Delieuvin, conservateur en chef chargé de la peinture italienne du 16ᵉ siècle au Musée du Louvre. Au Cœur de l'Histoire est réalisée par Pierre Cazalot. Rédaction en chef : Benjamin Delsol. Auteur du récit : Eloi Audoin-Rouzeau. Journaliste : Clara Leger.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Stéphane Bern raconte, suite à la disparition du Pape François, le destin de la basilique Saint-Pierre de Rome où son corps est exposé. Une basilique qui est le cœur spirituel du monde chrétien et l'un des plus grands monuments religieux à l'histoire jonchée de secrets... Mais qui était Saint Pierre ? Comment Saint Pierre est-il devenu une figure essentielle dans la chrétienté ? Quels mystères continuent d'entourer cette basilique ? Pour en parler, Stéphane Bern reçoit Christophe Dickès, historien du Vatican et spécialiste de Saint-Pierre. Au Cœur de l'Histoire est réalisée par Guillaume Vasseau. Rédaction en chef : Benjamin Delsol. Auteur du récit : Eloi Audoin-Rouzeau. Journaliste : Clara Leger.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Stéphane Bern raconte, suite à la disparition du Pape François, le destin de la basilique Saint-Pierre de Rome où son corps est exposé. Une basilique qui est le cœur spirituel du monde chrétien et l'un des plus grands monuments religieux à l'histoire jonchée de secrets... Mais qui était Saint Pierre ? Comment Saint Pierre est-il devenu une figure essentielle dans la chrétienté ? Quels mystères continuent d'entourer cette basilique ? Pour en parler, Stéphane Bern reçoit Christophe Dickès, historien du Vatican et spécialiste de Saint-Pierre. Au Cœur de l'Histoire est réalisée par Guillaume Vasseau. Rédaction en chef : Benjamin Delsol. Auteur du récit : Eloi Audoin-Rouzeau. Journaliste : Clara Leger.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Stéphane Bern raconte René Lalique, créateur de bijoux à la Belle Epoque qui a laissé son nom gravé sur des objets d'exception, et dans l'Histoire de l'art français… en devenant un véritable maître verrier ! En quoi René Lalique a-t-il inventé le bijou moderne ? Comment est-il passé maître dans l'art de la verrerie ? Comment a-t-il participé à la révolution industrielle ? Pour en parler, Stéphane Bern reçoit Véronique Brumm Schaich, directrice du musée Lalique et auteure du livre “René Lalique, le génie de la lumière” (Gallimard). Au Cœur de l'Histoire est réalisée par Loïc Vimard. Rédaction en chef : Benjamin Delsol. Auteure du récit : Albane Le Conte. Journaliste : Clara Léger.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Stéphane Bern raconte René Lalique, créateur de bijoux à la Belle Epoque qui a laissé son nom gravé sur des objets d'exception, et dans l'Histoire de l'art français… en devenant un véritable maître verrier ! En quoi René Lalique a-t-il inventé le bijou moderne ? Comment est-il passé maître dans l'art de la verrerie ? Comment a-t-il participé à la révolution industrielle ? Pour en parler, Stéphane Bern reçoit Véronique Brumm Schaich, directrice du musée Lalique et auteure du livre “René Lalique, le génie de la lumière” (Gallimard). Au Cœur de l'Histoire est réalisée par Loïc Vimard. Rédaction en chef : Benjamin Delsol. Auteure du récit : Albane Le Conte. Journaliste : Clara Léger.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Kia ora,Welcome to Friday's Economy Watch where we follow the economic events and trends that affect Aotearoa/New Zealand.I'm David Chaston and this is the international edition from Interest.co.nz.And today we lead with we are ending the week with Wall Street not finding much to like about future trade prospects, especially as policy shifts seem to be highly chaotic and involve personal retributions.US initial jobless claims rose last week to +195,000 when seasonal factors indicated it would fall. There are now just over 2 mln people claiming these benefits. This time last year there was just over 1.9 mln, a rise of +99,000.American consumer inflation expectations for the year ahead rose to 3.1% in July from 3% in June. This was held back only because of the widespread perception that petrol prices would fall. The median year-ahead expected change in food prices remained unchanged at 5.5%. Looking further ahead inflation expectations in fives rose to 2.9% from 2.6%.Meanwhile Q2 American labour productivity improved in data released today. It rose by 2.4% in the quarter following a revised -1.8% drop in the prior period. Analysts expected a +2% increase. Output increased by 3.7% (vs -0.6% in Q1) and hours worked increased by 1.3% (vs 1.2%).The US agricultural sector used to be a powerhouse export driver. But no more. Data released yesterday shows it has turned into a net importer, a trend that started in 2018 in the first Trump presidency. The first half of 2025 has now recorded its largest deficit on record, mainly on stuttering exports.Meanwhile, American consumer credit rose in June but only modestly. Total consumer credit rose by just +US$7.4 bln in the month, up from a +US$5.1 bln in May. These are minor changes and don't indicate any impending credit stress.Across the Atlantic in a tighter than expected vote, the Bank of England cut its policy rate by -25 bps to 4.0%. They have inflation running at 3.6% with a target of 2%. Five of the nine voting members voted for the cut, four wanted no-change. This was much closer than the 7:2 vote expected.In China, they are not only subsidising trade-in programs to help juice their domestic economy, now they are subsidising interest rates on personal loans. Consumer credit has not been traditionally popular in China, but young people are signing up much more freely. It is a sector that may grow to hold financial stability risks.Standard & Poor's have affirmed China's sovereign credit rating at A+ Stable. China's government gets a AAA rating from its own domestic ratings agencies, but Beijing was pleased anyway with the S&P result.Container freight rates fell -3% last week from the week before to be -58% lower than year-ago levels, although to be fair those were an unusual peak. Outbound from China was again the main weakness although outbound from the US is now showing up as a weakening trade too - and that starts with very low rates anyway. Bulk cargo rates were essentially unchanged over the past week and are now +18% higher than a year ago.The UST 10yr yield is now at 4.25%, up +3 bps from yesterday. The price of gold will start today at US$3,391/oz, up US$17 from yesterday.American oil prices have slipped back again, down another -US$1 to just on US$64/bbl with the international Brent price down at just over US$66.50/bbl.The Kiwi dollar is at 59.5 USc and up +10 bps from yesterday. Against the Aussie we are up +20 bps at 91.5 AUc. Against the euro we are up +10 bps at 51.1 euro cents. That all means our TWI-5 starts today at just on 67.3, up +20 bps.The bitcoin price started today at US$116,442 and up +0.8% from this time yesterday. Volatility over the past 24 hours has been modest at just under +/-1.1%.You can get more news affecting the economy in New Zealand from interest.co.nz.Kia ora. I'm David Chaston. And we will do this again on Monday.

Stéphane Bern raconte le destin - lié - de deux frères : Auguste et Louis Lumière qui, il y a 130 ans aujourd'hui, ont tourné le premier film de l'histoire du cinéma. Un très très court métrage rendu possible grâce à leur invention : le cinémascope, à la fois une caméra et un appareil pour projeter les images capturées, qui a fait leur succès… Qu'est-ce qui distingue l'invention des frères Lumière de toutes les autres ? Que voulait raconter le cinéma Lumière ? En quoi ont-ils inventé non seulement un objet, le cinématographe, mais aussi un nouveau monde ? Pour en parler, Stéphane Bern reçoit Thierry Frémaux, directeur de l'Institut Lumière de Lyon, délégué général du Festival de Cannes et réalisateur du film Lumière ! L'aventure continue. Au Cœur de l'Histoire est réalisée par Guillaume Vasseau. Rédaction en chef : Benjamin Delsol. Auteur du récit : Jean-Christophe Piot. Journaliste : Clara Leger.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Stéphane Bern raconte le destin - lié - de deux frères : Auguste et Louis Lumière qui, il y a 130 ans aujourd'hui, ont tourné le premier film de l'histoire du cinéma. Un très très court métrage rendu possible grâce à leur invention : le cinémascope, à la fois une caméra et un appareil pour projeter les images capturées, qui a fait leur succès… Qu'est-ce qui distingue l'invention des frères Lumière de toutes les autres ? Que voulait raconter le cinéma Lumière ? En quoi ont-ils inventé non seulement un objet, le cinématographe, mais aussi un nouveau monde ? Pour en parler, Stéphane Bern reçoit Thierry Frémaux, directeur de l'Institut Lumière de Lyon, délégué général du Festival de Cannes et réalisateur du film Lumière ! L'aventure continue. Au Cœur de l'Histoire est réalisée par Guillaume Vasseau. Rédaction en chef : Benjamin Delsol. Auteur du récit : Jean-Christophe Piot. Journaliste : Clara Leger.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Kia ora,Welcome to Thursday's Economy Watch where we follow the economic events and trends that affect Aotearoa/New Zealand.I'm David Chaston and this is the international edition from Interest.co.nz.And today we lead with news in search of short-term riches, the Cook Islands is establishing itself as a haven base for deep sea mining, it be used by both great powers.But first, American mortgage applications rose last week with a modest +3.1% gain from the prior week attributed to a small fall in benchmark mortgage interest rates. It was the stronger +5% refinance activity that drove the modest gain rather than new home purchases.Those benchmark rates may keep falling. There was slightly softer demand for the latest overnight US Treasury 10yr Note auction, but the resulting median yield came in at 4.20%, down from 4.31% at the prior equivalent event a month ago. However the yield is up on more recent levels.Separately, the NY Fed monitoring of global supply chain pressure eased again in July.In Canada, they are seeing residential real estate markets operating like we see here. For example Toronto sales transactions are rising (+13% in July from a year ago), but prices falling (-5.4% on the same basis).The Reserve Bank of India kept its key policy rate at 5.50% during its August meeting, now holding a neutral stance, following a larger-than-expected -50 bps decrease in June. There were no surprises here and the rate remains at its lowest level since August 2022. Easing inflation and the recent US tariff challenges were key considerations.Meanwhile, the US has doubled its tariffs on India to 50% as 'punishment' for buying Russian oil. Interestingly it has boosted Modi's standing at home in India and brought bi-partisan support for him in resisting the US.In China, they have brought in a ¥3,600 yuan (NZ$845) per year child care subsidy for under threes, designed to boost household consumption and ease pressure on family budgets. Encouraging childbirth is probably the core motivation for this subsidy. It is just another is a broadening range of consumer subsidies China is rolling out to support its economy and build domestic demand.EU retail sales volumes impressed in an overnight data release for June. They were up +3.1% on a volume basis, the best increase since September 2024. German gains were particularly strong, up +4.8% on the same volume basis.But new German factory orders again disappointed in June, down -1.0% in volume terms. Although this was twisted by some lumpy 'large' orders. Excluding those, the change is a gain of +0.5% in volume terms. (Large-scale items include aircraft, ships, trains, military vehicles).Australia said living costs rose for all type of households in June. Over the past year, all LCIs rose between +1.7% and +3.1%, slowing from annual rises of between +2.4% and +3.5% to the March 2025 quarter. In the South Pacific, the Cook Islands is becoming a renegade state. Its deal with China allows the Chinese to use it as a base for deep sea mining. Now the US is keen to use it in the same way. These great powers see “one of the most promising regions for deep-sea mineral deposits.” These nations are keen to plunder as far away from themselves as possible.The UST 10yr yield is now at 4.22%, up +2 bps from yesterday. The price of gold will start today at US$3,374/oz, down -US$5 from yesterday.American oil prices have slipped back again, down another -50 USc to just under US$65/bbl with the international Brent price holding at just over US$67.50/bbl.The Kiwi dollar is at 59.4 USc and up +40 bps from yesterday. Against the Aussie we are unchanged at 91.3 AUc. Against the euro we are also unchanged at 51 euro cents. That all means our TWI-5 starts today at just on 67.1, up +20 bps.The bitcoin price started today at US$115,465 and up +1.6% from this time yesterday. Volatility over the past 24 hours has been low at just under +/-0.9%.You can get more news affecting the economy in New Zealand from interest.co.nz.Kia ora. I'm David Chaston. And we will do this again tomorrow.

Kia ora,Welcome to Wednesday's Economy Watch where we follow the economic events and trends that affect Aotearoa/New Zealand.I'm David Chaston and this is the international edition from Interest.co.nz.And today we lead with news the equity markets and the bond markets are flashing quite different signals, and equity markets seem quite out of step with the operating economic data. When these vary, there is usually a reckoning, and that usually (but not always) results in an equity correction.But first up today, the overnight dairy auction brought results similar to what the derivatives market expected, maybe slightly better because of show early season strength in WMP demand and prices. Volumes sold were the highest since October 2024. And helping the tone was the fall in the NZD which boosted the rise in local currency. Overall the event ended up +0.7% in USD and up +1.5% in NZD. The industry will be satisfied the new season is off to a good start.On the butter demand front, there was a noted fall off in demand at these prices - except frim China and Middle East buyers. There is enough there to keep prices elevated, although to be fair the butter price did ease +3.8% at this event.Meanwhile, the widely watched American ISM services PMI unexpectedly fell in July 2025 from June, and the result was lower than expected. The services sector is now nearly stagnant, with seasonal and weather factors having a negative impact on business. A slowdown was most evident in the fall in new orders - activity is still operating faster than new orders are arriving so that is not great for the future. Not slowing are price increases, so all the signs of stagflation here. However, the internationally-benchmarked S&P Global/Markit version told a more upbeat story.US exports fell in June from May but the fall was only minor, and from a year ago there were up +3.3%. US imports fell more sharply in the month to be -1.4% below year-ago levels. But that only results in their trade deficit being back to mif 2024 levels. Or 2023 levels. The needle has moved very little.But the RCM/TIPP sentiment survey rose in July although the move was minor. It mirrored the month's equity markets and this index also hit a 4 year high.American household debt rose by +US$185 bln in the June quarter to a new record high of US$18.4 tln. That is now 60.6% of GDP. The flow of household debt into serious delinquency was mixed across debt types, with credit card and car loans holding steady, student loans continuing to rise, and mortgages edging up slightly.In India, their services PMI tells a booming story. International orders and overall sales rose sharply from the fastest increase in business activity for 11 months. However, price pressures re-accelerated, so this boom comes with inflation consequences. It's a report in sharp contrast to the lackluster American equivalents. "Someone" is quite envious of their success and is threatening sharply higher tariffs.Meanwhile Trump is signaling that their endless 'truce' with China will get another extension.And China delivered a positive data surprise yesterday, with the private Caixin services PMI rising and by more than expected. (Remember the official NBS services PMI eased lower.) The Caixin China General Services PMI rose in July from June's nine-month low with the fastest expansion in the services sector since May 2024, and with new business growing at the strongest pace in a year.That is in contrast to the EU services PMI which remains weak, although it is still expanding.Quarterly June data out today in Australia shows household spending rose at a good rate, up +5.1% from the same month a year ago - and the rate it rose from March was good too. Discretionary spending was strong. Western Australia was the only jurisdiction where spending fell. On a volume basis (after inflation's impact), it is up +0.7%.Join us at 10:45am for the New Zealand labour market report for June, although it might just confirm the tough operating environment we are in.The UST 10yr yield is now at 4.20%, up +1 bp from yesterday. The price of gold will start today at US$3,379/oz, up +US$7 from yesterday.American oil prices have slipped back again, down another -US$1 to just under US$65.50/bbl with the international Brent price just over US$67.50/bbl.The Kiwi dollar is at 59 USc and little-changed from yesterday. Against the Aussie we are down -30 bps at 91.3 AUc. Against the euro we are unchanged at 51 euro cents. That all means our TWI-5 starts today at just on 66.9, down -10 bps.The bitcoin price started today at US$113,625 and down -1.4% from this time yesterday. Volatility over the past 24 hours has been modest at just under +/-1.2%.You can get more news affecting the economy in New Zealand from interest.co.nz.Kia ora. I'm David Chaston. And we will do this again tomorrow.

Kia ora,Welcome to Tuesday's Economy Watch where we follow the economic events and trends that affect Aotearoa/New Zealand.I'm David Chaston and this is the international edition from Interest.co.nz.And today we lead with news tough economic news keeps coming, even during this lazy August vacation period in the northern hemisphere.First, in the US factory orders were expected to retreat in June, consistent with the labour market and PMI signals - and they did. They were down -4.8% from May, although they are still up +6.6% from a year ago. The June falls were largely driven by a -22% plunge in transportation equipment orders. This same data confirmed the earlier durable goods order decrease in June of -9.4%.We are awaiting important services PMIs for July and they are expected to be much better than those for their factory sector.American economic uncertainty is now well embedded in consumer behaviour. Some brands are really suffering, and causing large writedowns.Meanwhile, American vehicle sales rose in July to an annualised rate of 16.4 mln, slightly more than expected because they got a boost ahead of expected price increases from the August 1 tariff-taxes. But the boost was relatively minor, just +3.6% ahead of the same level in July 2024.In China, parts of the country are battling heavier-than-usual rainfall. And that includes Beijing itself, a city of 22 mln. Dozens of people have died in flooding already. They are expecting 200 mm of rain to fall over the next 24 hours, on top of what they have had which created their emergency. Beijing's normal annual rainfall is 600 mm.In Australia, the Melbourne Institute's inflation gauge survey result brought an unwelcome surprise. It surged +0.9% in July, the steepest rise since December 2023 and a sharp rebound from June's modest +0.1% increase. The RBA is unlikely to be impressed because even if inflation is within range it seems to be testing the upper end of that range and a rate cut could well push it up out-of-range. Still, financial markets are pricing in a full -25 bps cut for Tuesday, August 12 when the RBA next meets. And they have priced in two more by the end of 2025. At this time, given inflation is proving harder to lick, that seems unlikely. And in turn there could be many disappointed market traders - and mortgage holders - as the year unfolds.The UST 10yr yield is now at 4.19%, down -3 bps from yesterday.The price of gold will start today at US$3,372/oz, up +US$10 from yesterday.American oil prices have slipped back again, down -US$1 to just under US$66.50/bbl with the international Brent price just over US$68.50/bbl.The Kiwi dollar is at 59 USc and down -20 bps from yesterday. Against the Aussie we are down -10 bps at 91.4 AUc. Against the euro we are also down -10 bps at 51 euro cents. That all means our TWI-5 starts today at just on 67, down -10 bps as well.The bitcoin price started today at US$115,217 and up +0.9% from this time yesterday. Volatility over the past 24 hours has been low again at just under +/-0.7%.You can get more news affecting the economy in New Zealand from interest.co.nz.Kia ora. I'm David Chaston. And we will do this again tomorrow.

Kia ora,Welcome to Monday's Economy Watch where we follow the economic events and trends that affect Aotearoa/New Zealand.I'm David Chaston and this is the international edition from Interest.co.nz.And today we lead with news US President Trump is "making progress" is bending independent agencies (BLS, the US Fed) to respond to what is best for him, rather than the US economy.But the week ahead will all be focused locally on Wednesdays Household Labour Force survey results for July. Our jobless rate is expected to rise to 5.3% from 5.1% in June (and May). That would make it its highest since 2016 and exceeding anything we had in the pandemic period.Elsewhere the week will feature a raft of PMI and factory order releases. Plus, China will release key trade and inflation data.But the big economic driver for the week will be market reactions to Trump's tariff-war moves and his drive to bend both the Fed and the economic data agencies in the US to show fealty to him and avoid any negative reports. On Friday they sensed all this isn't good for the US economy and turned sharply risk averse even though corporate earnings reports have stayed positive.And that was because of Trump's response to official data he didn't like. He moved to fire the head of the data agency who reported it.Then a voting Fed official resigned, giving him a chance to twist more independence out of this crucial institution.The release of the July US labour market report showed the headline jobs gain was only +73,000 when +110,000 was expected. But worse, the June data was revised sharply lower to just +14,000 from the original +147,000. Their jobless rate edged higher to 4.2%. The number of people unemployed for at least 27 weeks has topped 1.8 mln now, the highest since the pandemic. Wage growth for the low-paid was unusually weak. This is a huge miss and there were sharp financial market reactions.Those are the seasonally adjusted numbers. The actual numbers are much worse, down -1,066,000 in July from June. To be fair much of that actual shrinkage is seasonal, but at 159.3 mln people employed, that is lower than in November 2024 when Trump won office.But with this July stumble in their labour market, it will be no surprise to know that the ISM factory PMI shows the same sharp retreat. In June this PMI was contracting with a 49.0 index level. It was expected to improve to a smaller contraction of 49.5. (An index level of 50 is the fulcrum between expansion and contraction.) But it went the other way, deepening its contraction to 48.0. Driving the retreat were new orders and order backlogs contracting, along with input costs increasing and exports falling. Overall, this is reporting their factory sector is contracting faster. (The internationally benchmarked S&P Global/Markit factory PMI version also reported a sharp drop info contraction in July, also largely on stagnating new order levels.)In China, like the official China factory PMIs had signaled, the independent Caixin PMI also signaled that their factory sector went backwards in July too. The Caixin survey isn't as negative as the official survey, but it now shows the overall sector in contraction. The Caixin survey tends to account better for mid-sized private manufacturers whereas the official survey includes the very large state-owned enterprises.China recognises the need to do more to stimulate internal consumption, and they are now committed to using subsidies as a key tool. Essentially they are subsidising trade-in prices to generate sales of new items. The target is to raise this subsidy level to ¥300 bln in 2025. On Friday they announced another ¥69 bln in ultra-long special treasury bonds will be issued for this purpose, the fourth tranche in the program.Another policy action announced on Friday involves their war on "involution", which they take to mean excessive or irresponsible competition involving a general race to the bottom. It was a feature of their housing crisis, and is a big worry for their car manufacturing industry. Top-down pressure to rein in this sort of behaviour is intense now. In fact, BYD is now indicating their production levels will be lower in future.However in Japan, Toyota has told suppliers that it aims to boost 2025 global production to about 10 million vehicles, underpinned by strong sales of hybrids despite concerns over the impact of American tariffs. (In the US, carmaker Ford is noting that tariffs are not helping them.)In Singapore, the latest PMI readings painted a mixed manufacturing outlook with the electronics sector in continued expansion whereas the overall manufacturing sector reverted to a marginal contraction. Declining now order levels caused the shift.In India, the growth of factory orders and production strengthened in July, driving their factory PMI up to an impressive 59.1, although that was a touch less than the result expected. Indian factories are easily the star of the show on a global basis.The EU released its July inflation data on Friday, and there were no surprises there with inflation stable at 2.0% in the Euro area. The overall level is still being restrained by falls in energy costs.Australian producer prices rose 3.4% over the past year to June, down from a 3.7% rate in the year to March, and down from a 4.8% rate in the year to June 2024. Cost pressures are still high, but they are easing, even if slowly.The UST 10yr yield is now at 4.22%, up +1 bps from Saturday, down -18 bps for the week.The price of gold will start today at US$3,362/oz, up +US$14 from Saturday.American oil prices have slipped back again, now just over US$67/bbl with the international Brent price holding at US$69.50/bbl. A week ago these prices were US$65 and US$68.50/bbl. OPEC has agreed a big increase in oil production. And we should probably note another fall in North American oil rigs in action, now down to their lowest level since September 2021.The Kiwi dollar is at 59.2 USc and up +20 bps from Saturday but down nearly -1c from a week ago. Over all of July the fall was -180 bps. Against the Aussie we are unchanged at 91.5 AUc. Against the euro we are down -40 bps at 51.1 euro cents. That all means our TWI-5 starts today at just on 67.1, unchanged from Saturday, down -60 bps for the weekThe bitcoin price started today at US$114,109 and up +0.8% from this time Saturday, but down -2.0% from a week ago. Volatility over the past 24 hours has been low at just under +/-1%.You can get more news affecting the economy in New Zealand from interest.co.nz.Kia ora. I'm David Chaston. And we will do this again tomorrow.

Kia ora,Welcome to Friday's Economy Watch where we follow the economic events and trends that affect Aotearoa/New Zealand.I'm David Chaston and this is the international edition from Interest.co.nz.And today we lead with news today is the day the US has promised to levy arbitrary tariffs but still no word about how Australia and New Zealand will fare. It's not the end of August 1 until later tomorrow in the US. In the meantime, Mexico has been the latest country to be granted a 90 day extension.Meanwhile, initial US jobless claims fell to 193,100 in the fourth week of July, just marginally more than seasonal factors would have accounted for. There are now 2.016 mln people on these benefits, +82,000 more than the 1.934 mln in the same week a year ago.US-based employers announced 62,075 job cuts in July, up +29% from June's 47,999 and up +140% from 25,885 announced in the same month last year. July's job cuts were also well above average for a July month since the pandemic.The US PCE price index rose +0.3% in June from May, the largest increase in four months, following an upwardly revised +0.2% gain in May. Prices for goods were up +0.4%, and prices for services rose +0.2%. The core PCE index, which excludes food and energy, also went up +0.3%, also its strongest monthly gain in four months. Year on year, the PCE was up +2.6%, the core PCE up +2.8%. With more broad tariffs ahead, plus firms now far less willing to absorb these burdens, the future track of US inflation looks like it has only upside.Personal disposable incomes rose +1.7% from June a year ago in the US, personal spending was up +2.1%.In the industrial heartland, the Chicago PMI contracted much less in July, after a good rise in new order levels. But it is still contracting, only slower.Canada may be being disrespected by its bully southern neighbour via tariff threats and economic pressure, but its economy is showing remarkable resilience. In May, their GDP eased just -0.1% while in June it rose +0.1%. This is a far better result for them than they may have expected given the taunts and penalties they have had to absorb. Unlike Mexico, they aren't getting any delay in US tariff changes.As expected, the Bank of Japan held its policy rate unchanged yesterday at 0.5%. The decision was unanimous, reflecting the central bank's cautious approach to policy normalisation.Japanese industrial production surged in June, and in a quite unexpected way. Year-on-year it was up +4.0%, month-on-month up +1.7%. A small retreat was expected.The official July PMIs for China were released yesterday, showing their factory sector contracting at a faster rate and their service sector expansion all but evaporating. These results are not disastrous, but they will worry Beijing all the same. The vibrancy they recently re-found isn't lasting.There were some very positive Australian retail trade data released yesterday. And oddly, this is the final data released for retail sales as they shift to their "Monthly household spending indicator" series. The final data for retail trade brought a +4.9% year-on-year burst in value terms, +1.5% in volume terms. These levels were far better than any analyst was expecting. The contrast with New Zealand is rather stark.There was a marked slowing in the growth of air travel in June, up +2.6% in June and half the +5.1% rise in the same month a year ago. The North American market was flat, but the Asia Pacific international market rose +7.2% and an outsized gain.The June air cargo market expanded little overall, up +0.8% from a year ago. But that was because of a sharp retreat in cargo volumes in North America (down -8.3% for domestic cargoes, down -6.1% in international cargoes). Elsewhere international cargo volumes rose +1.6% and Asia Pacific volumes were up +8.3%.Container freight rates were little changed last week (-1%) with outbound rates from China the weakest segment. From a year ago these rates are now -56% lower although to be fair they were unusually high a year ago on Red Sea security problems. Bulk freight rates fell -5.3% over past week from the prior week to be +13% higher than year-ago levels.It's probably worth noting that after the large fall in the copper price we noted yesterday, there has been no bounce - it is still falling.The UST 10yr yield is now at 4.36%, down -1 bp from yesterday. The price of gold will start today at US$3,294/oz, up +US$17 from yesterday.American oil prices have slipped back -US$1.50 at just on US$69/bbl with the international Brent price is now at just on US$71.50/bbl.The Kiwi dollar was at 58.9 USc and and unchanged from yesterday. Against the Aussie we are up +10 bps at 91.7 AUc. Against the euro we are unchanged at 51.6 euro cents. That all means our TWI-5 starts today at just on 67.4, up +20 bps from yesterday helped by a rise against the yen which fell back after their central bank meeting.The bitcoin price started today at US$117,775 and essentially unchanged again (+US$9) from this time yesterday. Volatility over the past 24 hours has been modest at +/-1.2%.You can get more news affecting the economy in New Zealand from interest.co.nz.Kia ora. I'm David Chaston. And we will do this again on Monday.

Kia ora,Welcome to Thursday's Economy Watch where we follow the economic events and trends that affect Aotearoa/New Zealand.I'm David Chaston and this is the international edition from Interest.co.nz.And today we lead with news a no-change Fed has brought sharp market reactions, bolstered by an odd tariff twist.As expected, the US central bank left its key policy rates unchanged at the 4.25%–4.50% target range for a fifth consecutive meeting. They see the data pointing to 'a moderation in economic activity' during the first half of the year, contrasting with earlier assessments that growth was proceeding 'at a solid pace'. They noted that the unemployment rate remains low while inflation remains elevated, and uncertainty about the economic outlook persists. The vote was 9-2 with both dissenters wanting a lower rate and both wanting to be chosen by Trump to replace Powell.Markets are still digesting the Fed signals, but immediately after the US dollar rose although not significantly, the UST 10yr yield was little-changed initially then rose but only slightly, and the S&P500 rose but then equally quickly gave that bump up to now be lower. Gold kept falling. Bitcoin yawned, holding in the unchanged level it has had for the past three weeks. But then it woke up and fell out of that range, down -1.3%.Although US home loan interest rates were unchanged last week, mortgage applications fell, both for refinancing and for new purchases. And the June pending home sales report also out today paints a worrying picture for their housing sector with sales -2.8% lower from a year ago. Eight of the last twelve months have recorded year-on-year decreases.The July labour market report will be released on Saturday (NZT) and is expected to record a modest +110,000 jobs growth. Today the precursor ADP Employment Report was released suggesting private payrolls grew +104,000. (This ADP report is a good tracker of the non-farm payrolls report over the longer term, but not so reliable for any current month.)The first look at the Q2-2025 US GDP growth rate is out, showing a +3.0% rise, and better than the expected +2.4% result. But almost all of this is due to rising imports (+5%). Consumer spending contributed less than +1%. Investment activity was -3% negative in this result. Public spending and exports both made almost zero contribution. Although +3% is 'good' it is an unhealthy twist although that may not last. Of more concern is the dive in investment.North of the border, the Canadian central bank also reviewed its monetary policy position overnight, and it too held its rate unchanged at 2.75%.In the EU, the July sentiment surveys were out for the bloc and while they 'improved' in fact they remain in their long term range. So essentially, no change.In Singapore, their central bank equivalent, the Monetary Authority of Singapore kept its policy stance unchanged in yesterday's update.In Australia, and led by a fall in services inflation, overall CPI inflation dropped to 2.1% in Q2 2025 from 2.4% in the prior two periods, marking its lowest figure since Q1 2021 and below forecasts of 2.2%. June inflation alone was only +1.9% above year ago levels. Today's data removes any awkwardness posed by inflation remaining too high for the RBA and they are now very much more likely to cut by -25 bps on August 12 to 3.60%.On the tariff-war front, the US has imposed a 50% tariff on copper imported into the US - but then made a bewildering exception, for refined copper. Traders had been stockpiling copper ahead of this decision but weren't expecting the exception. So there is far more refined copper in the US than they need at a cost they don't need. It has caused havoc in the copper price overnight with an immediate -20% drop.The US imposed a 25% tariff on imports from India.Talks with China have been inconclusive in Stockholm and will no doubt drag on unresolved over the '90 day extension' period. China will count that as a win.The UST 10yr yield is now at 4.37%, up +4 bps from yesterday. The price of gold will start today at US$3,277/oz, down -US$50 from yesterday with most of it after the US Fed decision.American oil prices have risen another +US$1.50 at just under US$70.50/bbl with the international Brent price is now at just on US$73.50/bbl.The Kiwi dollar was at 59.2 USc and down -30 bps from yesterday pre the Fed. Then it fell another -30 bps to 58.9 USc. Against the Aussie we are up +20 bps at 91.6 AUc. Against the euro we are unchanged at 51.6 euro cents. That all means our TWI-5 starts today at just on 67.2, down another -30 bps from yesterday.The bitcoin price started today at US$117,766 and essentially unchanged again (+US$51) from this time yesterday. But after the US Fed decision, it took a -1.3% tumble. Volatility over the past 24 hours rose to +/-1.2%.You can get more news affecting the economy in New Zealand from interest.co.nz.Kia ora. I'm David Chaston. And we will do this again tomorrow.

Kia ora,Welcome to Wednesday's Economy Watch where we follow the economic events and trends that affect Aotearoa/New Zealand.I'm David Chaston and this is the international edition from Interest.co.nz.And today we lead with news the IMF says global growth is projected at 3.0% for 2025 and 3.1% in 2026, an upward revision from the April 2025 World Economic Outlook. This reflects front-loading ahead of tariffs, lower effective tariff rates, better financial conditions, and fiscal expansion in some major jurisdictions.But first, the overnight GDT Pulse dairy prices came in without the signaled drop in WMP prices by the derivatives market. In fact it rose +1% from the prior event. The SMP price however fell -1%. So in fact little net movement.And the Stockholm US-China tariff negotiations are to be extended, essentially ignoring the US imposed August 1 deadline. And the US-EU 'deal' wasn't 'done' as the Whitehouse claimed. More 'horse-trading' is being scheduled.The growth steam is slowly leaking from the Redbook retail index, up +4.9% last week from this time last year. Most of this will be goods inflation.US exports rose +3.4% in June from a year ago whereas US imports were up +0.3% on the same basis. That reduced their merchandise trade deficit to -US$87 bln and back to about where it was at the start of 2024. Without the +11% rise in aircraft exports there would have been little improvement.The number of job openings in the US fell by -275,000 from May to 7.4 mln in June, below market expectations of 7.55 mln. Their quit rate fell to a six month low. Expectations for the July non-farm payrolls are pretty modest at +110,000, taking them back to early 2025 levels.The latest Conference Board survey of consumer sentiment, for July, was little changed. But almost 19% of those surveyed indicated that jobs were hard to get in July, up from 14.5% in January. This group thought inflation was running at 5.8% currently, and is likely to go higher.There was a very well supported US Treasury bond auction overnight, for their seven year Note. But investors still wanted higher yields with the median coming in at 4.06%, up from 3.96% at the prior equivalent event a month ago.But expect rising pressure from the demand side. The US Treasury said during the July - September 2025 quarter, they expect to borrow US$1.007 tln in privately-held net marketable debt, assuming an end-of-September cash balance of US$850 bln - which may be optimistic. This new borrowing estimate is +US$453 bln higher than they announced in April so it is rising faster than even they expected, primarily due to the lower beginning-of-quarter cash balance and projected lower net cash flows.In Europe, the latest ECB survey of inflation expectations has them well contained, coming in at 2.6% for the year ahead, the lowest in four months. Policymakers there are not battling high inflation expectations.Later today, Australia will release its Q2 CPI inflation rate, expected to be 2.2% and down from the 2.4% in Q1-2025.The UST 10yr yield is now at 4.33%, down -9 bps from yesterday.The price of gold will start today at US$3,327/oz, up +US$18 from yesterday.American oil prices have risen +US$2.50 at just under US$69/bbl with the international Brent price is now at just over US$72/bbl.The Kiwi dollar is now at 59.6 USc and down -10 bps from yesterday. Against the Aussie we are down -20 bps at 91.4 AUc. Against the euro we are up +10 bps at 51.6 euro cents. That all means our TWI-5 starts today at just on 67.5, down another -10 bps from yesterday.The bitcoin price starts today at US$117,725 and essentially unchanged (+US$61) from this time yesterday. Volatility over the past 24 hours has remained low at just on +/-0.8%.You can get more news affecting the economy in New Zealand from interest.co.nz.Kia ora. I'm David Chaston. And we will do this again tomorrow.

In this episode I discuss R Shiny and how it can be used for building clinical pharmacology tools. I provide an overview of the technology, suggest a few example use cases, and then walk through a specific practical example of predicting AUC and Cmax for future doses from observed data. I end with a discussion of the benefits and challenges of using R Shiny for clinical pharmacology tools. Links discussed in the show:Basics about R ShinyShinyapps.io for hosting shiny apps Example R Shiny app by Samer Mouskassi: ggplot with your dataExample R Shiny app for AUC-Cmax predictions You can connect with me on LinkedIn and send me a message Send me a message Sign up for my newsletter Copyright Teuscher Solutions LLCAll Rights Reserved

Kia ora,Welcome to Tuesday's Economy Watch where we follow the economic events and trends that affect Aotearoa/New Zealand.I'm David Chaston and this is the international edition from Interest.co.nz.And today we lead with talks are underway in Stockholm between the US and China over a trade/tariff deal. Prospects are not high.And the recent EU-US deal has the makings of unravelling. Both France and Germany are unhappy about the outcome, made worse by the US claiming verbally pharmaceuticals have been excluded when the EU negotiators said they were not excluded from the 15% written deal.The big casualty in all of these deals, including the Japanese one, is trust in the US. Smartarse public commenting by the US president - even some of his advisers - means the deals struck are unlikely to be respected by the US or trusted by the others. The result isn't "a deal", it is a fluid mess.New Zealand's situation in all this will be a footnote, probably sometime on Saturday.In the US, the Dallas Fed's factory survey improved sharply in July, but this was all about higher production. New orders are still contracting, even if at a slower rate. Elevated input price pressures continued in July. Improved sentiment is driving the raised output even in the absence of a pickup in new orders.Financial market eyes are now turning to Thursday's (NZT) US Federal Reserve meeting and decisions. Despite the overt Whitehouse pressure, financial market pricing shows virtually no-one is pricing in a rate cut.In Canada, wholesale sales came in better than expected, up +0.7% in June from May when a -0.2% retreat was anticipated. But despite that good recent gain, they will still be lower than in June 2024.Across the Pacific, from 2022 to 2024, Taiwanese consumer confidence rose. But since October 2024 it has been falling. However the July survey rose, the first break in the recent down-trend. It wasn't a big move from June, but they will take it.In China, they are taking something they don't want. Foreign direct investment recorded another net outflow in June, and a worse one than the highly unusual April net outflow. The reasonable start to 2025 is being undone faster now. In the six months to June they have had a net inflow of US$42.3 bln. In 2024 they had more than that in just the first three months and even that was much weaker than in 2023 (US$98 bln) or 2022 (US$112 bln). Fleeing investors isn't a good look for China.Indian industrial production expanded a rather weak +1.5% in June from a year ago, held back by surprisingly weak mining (coal) production.. In their factories however, the story is much better with manufacturing production us +3.9% from a year ago, a better rise than in May although less than the +4.5% expected.The UST 10yr yield is now at 4.42%, up +3 bps from yesterday.The price of gold will start today at US$3,309/oz, down -US$27 from yesterday.American oil prices have risen +US$1.50 at just on US$66.50/bbl with the international Brent price is now at just under US$70/bbl.The Kiwi dollar is now at 59.7 USc and down -½c from yesterday and back to where it was a week ago. Against the Aussie we are unchanged at 91.6 AUc. Against the euro we are up +30 bps at 51.5 euro cents. That all means our TWI-5 starts today at just on 67.6, down -10 bps from yesterday.The bitcoin price starts today at US$117,664 and down -1.3% from this time yesterday. Volatility over the past 24 hours has remained low at just on +/-0.9%.You can get more news affecting the economy in New Zealand from interest.co.nz.Kia ora. I'm David Chaston. And we will do this again tomorrow.

Kia ora,Welcome to Monday's Economy Watch where we follow the economic events and trends that affect Aotearoa/New Zealand.I'm David Chaston and this is the international edition from Interest.co.nz.And today we lead with news - despite the US tariff news flooding the zone - the rest of the world economy is find a way to carry on.But first we should note that a 15% tariff deal seems to have been concluded between the EU and the US but one that excludes drugs and aluminium. It looks very like the Japanese deal. And the tariff tussle between China and the US looks like it has been extended another 90 days. The pressure will be on European and Japanese companies to become 15% more efficient, but US companies will relax, allowed to be 15% less efficient in their home markets. In the intermediate term this won't be good for global US competitiveness.In a look ahead this coming week, we will get our usual New Zealand monthly business and consumer sentiment survey updates. And our big end-of-month data dump from the RBNZ accentuated because it is end of quarter data. In Australia, it will be all about retail trade and inflation metrics.And Wall Street will be very busy with many more large companies releasing earnings.But the big interest rate influence will be from the central bank decisions from the US (no change expected), Japan (no change), and Canada (also no change). In all three cases the real interest will be on their commentary.Underlying all this will be July PMIs from most major economies, plus more Q2 GDP data, and many inflation updates.Over the weekend China released industrial profits data to June. They reported another slide, down -4.3% from June a year ago, the second straight monthly decline, amid persistent deflation pressures and growing trade uncertainty. State-owned enterprises experienced steeper losses while profit growth in the private sector slowed markedly. Profit gains were recorded in many sectors but one interesting one was in agriculture where profits were up more than +20%.In Russia, and as expected, they cut their policy rate by -200 bps to 18%. They signaled another cut is likely in 2025. They see disinflation on the rise, and household consumption lower. Part of that is due to the size of the diaspora of working aged men trying to avoid the death trap of the attempted invasion of Ukraine.In Europe, the ECB's survey of professional forecasters shows they don't expect much change in the coming year with things constrained by trade questions. They see inflation easing slightly, mainly due to the tariff effects, but GDP growth slightly stronger in the short term.The Ifo Business Climate Index for Germany edged up in July from June, to the highest level since May 2024. But the report was still full of cautious sentiment.In the US and as expected durable goods orders fell back in June after the May spike. Apart from the aircraft and defense sectors, it remained pretty ho-hum. New orders rose just +0.1%. Non-defense non-aircraft orders for capital goods fell when a rise was anticipated.The UST 10yr yield is now at 4.39%, unchanged from Saturday.The price of gold will start today at US$3,336/oz, down -US$2 from Saturday.American oil prices have stayed softish at just on US$65/bbl with the international Brent price is still at just under US$68.50/bbl.The Kiwi dollar is now at 60.2 USc and up +10 bps from Saturday and up almost +½c from a week ago. Against the Aussie we are unchanged at 91.6 AUc. Against the euro we are stable at 51.2 euro cents. That all means our TWI-5 starts today at just on 67.7, unchanged from Saturday but up +20 bps from a week ago.The bitcoin price starts today at US$119,210 and up +2.4% from this time Saturday. Volatility over the past 24 hours has been low at just on +/-0.7%.You can get more news affecting the economy in New Zealand from interest.co.nz.Kia ora. I'm David Chaston. And we will do this again tomorrow.

Au Cœur de l'Histoire est un podcast Europe 1. - Présentation : Virginie Girod - Production : Armelle Thiberge - Réalisation : Clément Ibrahim - Diffusion : Estelle Lafont - Composition du générique : Julien Tharaud - Promotion et coordination des partenariats : Marie Corpet - Visuel : Sidonie Mangin Des heures et des heures d'Au Cœur de l'Histoire à écouter !  Découvrez  Au Coeur de l'Histoire +, une nouvelle offre pour accéder en avant-première aux nouveaux épisodes et en exclusivité à nos meilleures archives sur Versailles ou Napoléon par exemple. L'abonnement Au Cœur de l'Histoire + est disponible sur Apple Podcasts en cliquant ici                    Comment s'abonner ? Où écouter ? Quels sont les avantages d'Au Cœur de l'Histoire + ? Le mode d'emploi est disponible ici. Vous voulez écouter les autres épisodes d'Au Cœur de l'Histoire ? >> Retrouvez-les sur notre site Europe1.fr et sur Apple Podcasts, Spotify, Deezer, Amazon Music, Dailymotion et YouTube, ou vos plateformes habituelles d'écoute. >> Retrouvez ici le mode d'emploi pour écouter tous les podcasts d'Europe 1   Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Au Cœur de l'Histoire est un podcast Europe 1. - Présentation : Virginie Girod - Production : Armelle Thiberge - Réalisation : Christophe Daviaud - Diffusion : Estelle Lafont - Composition du générique : Julien Tharaud - Promotion et coordination des partenariats : Marie Corpet - Visuel : Sidonie Mangin   Des heures et des heures d'Au Cœur de l'Histoire à écouter !  Découvrez  Au Coeur de l'Histoire +, une nouvelle offre pour accéder en avant-première aux nouveaux épisodes et en exclusivité à nos meilleures archives sur Versailles ou Napoléon par exemple. L'abonnement Au Cœur de l'Histoire + est disponible sur Apple Podcasts en cliquant ici                    Comment s'abonner ? Où écouter ? Quels sont les avantages d'Au Cœur de l'Histoire + ? Le mode d'emploi est disponible ici. Vous voulez écouter les autres épisodes d'Au Cœur de l'Histoire ? >> Retrouvez-les sur notre site Europe1.fr et sur Apple Podcasts, Spotify, Deezer, Amazon Music, Dailymotion et YouTube, ou vos plateformes habituelles d'écoute. >> Retrouvez ici le mode d'emploi pour écouter tous les podcasts d'Europe 1   Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Au Cœur de l'Histoire est un podcast Europe 1. - Présentation et écriture : Virginie Girod - Production : Armelle Thiberge - Réalisation : Nicolas Gaspard - Diffusion : Estelle Lafont - Composition du générique : Julien Tharaud - Promotion et coordination des partenariats : Marie Corpet - Visuel : Sidonie Mangin Ressources en ligne Geneviève Zaepfell, Mon combat psychique Geneviève Zaepfell, Arrangez-vous là-haut ! "Légendes et fantômes de l'Ouest. Un manoir régi par l'occultisme en Ille-et-Vilaine" - Ouest France Geneviève Zaepffel - Encyclopédie de Brocéliande Philippe Baudouin et Gaspard Laurent, « Bureaumancie », Terrain, Hors-série | 2021 Des heures et des heures d'Au Cœur de l'Histoire à écouter !  Découvrez  Au Coeur de l'Histoire +, une nouvelle offre pour accéder en avant-première aux nouveaux épisodes et en exclusivité à nos meilleures archives sur Versailles ou Napoléon par exemple. L'abonnement Au Cœur de l'Histoire + est disponible sur Apple Podcasts en cliquant ici                    Comment s'abonner ? Où écouter ? Quels sont les avantages d'Au Cœur de l'Histoire + ? Le mode d'emploi est disponible ici. Vous voulez écouter les autres épisodes d'Au Cœur de l'Histoire ? >> Retrouvez-les sur notre site Europe1.fr et sur Apple Podcasts, Spotify, Deezer, Amazon Music, Dailymotion et YouTube, ou vos plateformes habituelles d'écoute. >> Retrouvez ici le mode d'emploi pour écouter tous les podcasts d'Europe 1 Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Au Cœur de l'Histoire est un podcast Europe 1. - Présentation : Virginie Girod - Production : Armelle Thiberge - Réalisation : Clément Ibrahim - Diffusion : Estelle Lafont - Composition du générique : Julien Tharaud - Promotion et coordination des partenariats : Marie Corpet - Visuel : Sidonie Mangin Des heures et des heures d'Au Cœur de l'Histoire à écouter !  Découvrez  Au Coeur de l'Histoire +, une nouvelle offre pour accéder en avant-première aux nouveaux épisodes et en exclusivité à nos meilleures archives sur Versailles ou Napoléon par exemple. L'abonnement Au Cœur de l'Histoire + est disponible sur Apple Podcasts en cliquant ici                    Comment s'abonner ? Où écouter ? Quels sont les avantages d'Au Cœur de l'Histoire + ? Le mode d'emploi est disponible ici Vous voulez écouter les autres épisodes d'Au Cœur de l'Histoire ? >> Retrouvez-les sur notre site Europe1.fr et sur Apple Podcasts, Spotify, Deezer, Amazon Music, Dailymotion et YouTube, ou vos plateformes habituelles d'écoute. >> Retrouvez ici le mode d'emploi pour écouter tous les podcasts d'Europe 1   Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Au Cœur de l'Histoire est un podcast Europe 1. - Présentation : Virginie Girod - Production : Armelle Thiberge - Réalisation : Christophe Daviaud - Diffusion : Estelle Lafont - Composition du générique : Julien Tharaud - Promotion et coordination des partenariats : Marie Corpet - Visuel : Sidonie Mangin Des heures et des heures d'Au Cœur de l'Histoire à écouter !  Découvrez  Au Coeur de l'Histoire +, une nouvelle offre pour accéder en avant-première aux nouveaux épisodes et en exclusivité à nos meilleures archives sur Versailles ou Napoléon par exemple. L'abonnement Au Cœur de l'Histoire + est disponible sur Apple Podcasts en cliquant ici                    Comment s'abonner ? Où écouter ? Quels sont les avantages d'Au Cœur de l'Histoire + ? Le mode d'emploi est disponible ici. Vous voulez écouter les autres épisodes d'Au Cœur de l'Histoire ? >> Retrouvez-les sur notre site Europe1.fr et sur Apple Podcasts, Spotify, Deezer, Amazon Music, Dailymotion et YouTube, ou vos plateformes habituelles d'écoute. >> Retrouvez ici le mode d'emploi pour écouter tous les podcasts d'Europe 1   Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Bienvenue dans ce nouvel épisode d'«Au Cœur de l'Histoire» ! Ce matin, nous vous emmenons à la rencontre d'un personnage clé du XVIIe siècle français : Henri de La Tour d'Auvergne, plus connu sous le nom de maréchal de Turenne.Dès son plus jeune âge, Turenne baigne dans un environnement marqué par les conflits. Né dans une famille protestante, il grandit au cœur de la guerre de Trente Ans, un vaste conflit qui ravage l'Europe pendant trois décennies. Très jeune, il manifeste des qualités de stratège et d'organisateur qui ne tardent pas à être remarquées. Après avoir fait ses armes auprès de son oncle aux Pays-Bas, il rejoint l'armée française et gravit rapidement les échelons, devenant l'un des plus brillants généraux de son temps.Sous les règnes de Louis XIII et de Louis XIV, Turenne va jouer un rôle déterminant dans les conflits qui opposent la France à l'Espagne et à l'Autriche. Ses victoires décisives, notamment lors de la guerre de Hollande, lui valent une renommée sans égale. Tacticien hors pair, Turenne privilégie une approche indirecte, cherchant à désorganiser et à surprendre l'ennemi plutôt que de l'affronter de front.

Bienvenue dans ce nouvel épisode d'«Au Cœur de l'Histoire» ! Ce matin, nous vous emmenons à la rencontre d'un personnage clé du XVIIe siècle français : Henri de La Tour d'Auvergne, plus connu sous le nom de maréchal de Turenne.Dès son plus jeune âge, Turenne baigne dans un environnement marqué par les conflits. Né dans une famille protestante, il grandit au cœur de la guerre de Trente Ans, un vaste conflit qui ravage l'Europe pendant trois décennies. Très jeune, il manifeste des qualités de stratège et d'organisateur qui ne tardent pas à être remarquées. Après avoir fait ses armes auprès de son oncle aux Pays-Bas, il rejoint l'armée française et gravit rapidement les échelons, devenant l'un des plus brillants généraux de son temps.Sous les règnes de Louis XIII et de Louis XIV, Turenne va jouer un rôle déterminant dans les conflits qui opposent la France à l'Espagne et à l'Autriche. Ses victoires décisives, notamment lors de la guerre de Hollande, lui valent une renommée sans égale. Tacticien hors pair, Turenne privilégie une approche indirecte, cherchant à désorganiser et à surprendre l'ennemi plutôt que de l'affronter de front.

BUFFALO, NY – July 1, 2025 – A new #review was #published in Volume 16 of Oncotarget on June 17, 2025, titled “Optimizing enfortumab vedotin plus pembrolizumab therapy.” First authors Elias Antoine Karam of the Gustave Roussy and Saint-Joseph University of Beirut and Yaghi César Céline from the Saint-Joseph University of Beirut, along with their colleagues, reviewed recent developments about treating advanced urothelial carcinoma (aUC), an aggressive form of bladder cancer. Their review highlights how combining enfortumab vedotin and pembrolizumab as a first-line treatment offers a major improvement for patients with limited options and poor prognoses. Advanced urothelial cancer has traditionally been treated with platinum-based chemotherapy, which often causes serious side effects and offers limited long-term benefit. Many patients are even ineligible for it due to underlying health conditions. The new combination presents a more effective and better-tolerated alternative, as shown in recent clinical trials reviewed by the authors. Enfortumab vedotin targets Nectin-4, a protein present in most urothelial cancer cells, delivering a cancer-killing agent directly into tumors. Pembrolizumab helps the immune system detect and destroy cancer cells. Together, they have shown strong results in extending survival with fewer serious side effects than chemotherapy. These findings led to FDA approval in 2023 for use in a broad range of patients, including those unable to tolerate traditional treatments. “In the phase II KEYNOTE-052 study, pembrolizumab demonstrated significant efficacy as initial therapy in patients with aUC who were ineligible for a cisplatin-based regimen.” The review also compares this new approach with other evolving strategies, such as therapies using nivolumab and chemotherapy combinations. Among current first-line options, enfortumab vedotin and pembrolizumab have produced the most promising outcomes. However, the best course of action following disease progression remains unclear. Other important challenges raised in the review include the high cost of the new therapies, limited patient access to them, and the absence of reliable biomarkers to predict individual response. The authors call for further studies to refine treatment strategies and explore blood-based tools that could guide therapy decisions and minimize side effects. This review offers a clear summary of how recent clinical advances are reshaping the treatment of aUC. It reflects a shift away from traditional chemotherapy toward immunotherapy and targeted, personalized treatments that aim to extend survival and improve quality of life. DOI - https://doi.org/10.18632/oncotarget.28741 Correspondence to - Elias Antoine Karam - eliaskaram18@gmail.com Video short - https://www.youtube.com/watch?v=VrTXaF2qW2k Sign up for free Altmetric alerts about this article - https://oncotarget.altmetric.com/details/email_updates?id=10.18632%2Foncotarget.28741 Subscribe for free publication alerts from Oncotarget - https://www.oncotarget.com/subscribe/ Keywords - cancer, advanced urothelial carcinoma (aUC), enfortumab vedotin, pembrolizumab, treatment strategies, bladder cancer To learn more about Oncotarget, please visit https://www.oncotarget.com and connect with us: Facebook - https://www.facebook.com/Oncotarget/ X - https://twitter.com/oncotarget Instagram - https://www.instagram.com/oncotargetjrnl/ YouTube - https://www.youtube.com/@OncotargetJournal LinkedIn - https://www.linkedin.com/company/oncotarget Pinterest - https://www.pinterest.com/oncotarget/ Reddit - https://www.reddit.com/user/Oncotarget/ Spotify - https://open.spotify.com/show/0gRwT6BqYWJzxzmjPJwtVh MEDIA@IMPACTJOURNALS.COM

Pinky Selim is a banker by profession, a dancer by passion, and the founder of the AUC Alumni Folklore Group, a troupe dedicated to reviving Egyptian folkloric dance. While studying at the American University in Cairo, she was deeply involved in the university's folklore club, and after graduation, she couldn't imagine letting go of this art form. In 2013, with the support of AUC's Alumni Office, she launched AUC Alum Folk to preserve and celebrate Egyptian heritage through performance and education. Inspired by legends like Mahmoud Reda and Farida Fahmy, Pinky has choreographed and staged numerous shows that bring folklore to life for new generations. As a proud mother and twin sister, she leads a growing troupe of dancers of all ages, teaching workshops and organizing performances that honor the richness and diversity of Egyptian folk traditions.In this episode you will learn about:- How a simple alumni club became a full dance company- The deep influence of her father on Pinki's view of music and culture- The growing disconnection between young Egyptians and their own cultural heritage- Why teaching folklore felt urgent in a culture where kids mock their own language- What it takes to lead amateurs who dance like prosShow Notes to this episode:Find Pinky Selim on Instagram, and Instagram page of AUC Alumni Folklore.Visit Bellydance.com today: you'll always find something fresh, whether you're looking for costumes, practice wear, veils, hip scarves, jewelry, or music.Details and training materials for the BDE castings are available at www.JoinBDE.comFollow Iana on Instagram, FB, and Youtube . Check out her online classes and intensives at the Iana Dance Club.Find information on how you can support Ukraine and Ukrainian belly dancers HERE.Podcast: www.ianadance.com/podcast

Dr. Allison Zibelli and Dr. Rebecca Shatsky discuss advances in breast cancer research that were presented at the 2025 ASCO Annual Meeting, including a potential new standard of care for HER2+ breast cancer, the future of ER+ breast cancer management, and innovations in triple negative breast cancer therapy. Transcript Dr. Allison Zibelli: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Allison Zibelli, your guest host of the podcast today. I'm an associate professor of medicine and a breast medical oncologist at the Sidney Kimmel Comprehensive Cancer Center at Jefferson Health. There was a substantial amount of exciting breast cancer data presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Rebecca Shatsky today to discuss some of these key advancements. Dr. Shatsky is an associate professor of medicine at UC San Diego and the head of breast medical oncology at the UC San Diego Health Moores Cancer Center, where she also serves as the director of the Breast Cancer Clinical Trials Program and the Inflammatory and Triple-Negative Breast Cancer Program.  Our full disclosures are available in the transcript of this episode. Dr. Shatsky, it's great to have you on the podcast today. Dr. Rebecca Shatsky: Thanks, Dr. Zibelli. It's wonderful to be here. Dr. Allison Zibelli: So, we're starting with DESTINY-Breast09, which was trastuzumab deruxtecan and pertuzumab versus our more standard regimen of taxane, trastuzumab pertuzumab for first-line treatment of metastatic HER2-positive breast cancer. Could you tell us a little bit about the study? Dr. Rebecca Shatsky: Yeah, absolutely. So, this was a long-awaited study. When T-DXd, or trastuzumab deruxtecan, really hit the market, a lot of these DESTINY-Breast trials were started around the same time. Now, this was a global, randomized, phase 3 study presented by Dr. Sara Tolaney from the Dana-Farber Cancer Institute of Harvard in Boston. It was assessing essentially T-DXd in the first-line setting for metastatic HER2-positive breast cancer in addition to pertuzumab. And that was randomized against our standard-of-care regimen, which was established over a decade ago by the CLEOPATRA trial, and we've all been using that internationally for at least the past 10 years. So, this was a large trial, and it was one-to-one-to-one of patients getting T-DXd plus pertuzumab, T-DXd alone, or THP, which mostly is used as docetaxel and trastuzumab and pertuzumab every three weeks for six cycles. And this was in over 1,000 patients; it was 1,159 patients with metastatic HER2-positive breast cancer. This was a very interesting trial. It was looking at the use of trastuzumab deruxtecan, but patients were started on this treatment for their first-line metastatic HER2-positive breast cancer with no end date to their T-DXd. So, it was, you know, you were started on T-DXd every 3 weeks until progression. Now, CLEOPATRA is a little bit different than that, though, as we know. So, CLEOPATRA has a taxane plus trastuzumab and pertuzumab. But generally, patients drop the taxane after about six to seven cycles because, as we know, you can't be really on a taxane indefinitely. You get pretty substantial neuropathy as well as cytopenias, other things that end up happening. And so, in general, that regimen has sort of a limited time course for its chemotherapy portion, and the patients maintained after the taxane is dropped on their trastuzumab and their pertuzumab, plus or minus endocrine therapy if the investigator so desires. And the primary endpoint of the trial was progression-free survival by blinded, independent central review (BICR) in the intent-to-treat population. And then it had its other endpoints as overall survival, investigator-assessed progression-free survival, objective response rates, and duration of response, and of course, safety. As far as the results of this trial, so, I think that most of us key opinion leaders in breast oncology were expecting that this was going to be a positive trial. And it surely was. I mean, this is a really, really active drug, especially in HER2-positive disease, of course. So, the DESTINY-Breast03 data really established that, that this is a very effective treatment in HER2-positive metastatic breast cancer. And this trial really, again, showed that. So, there were 383 patients that ended up on the trastuzumab plus deruxtecan plus pertuzumab arm, and 387 got THP, the CLEOPATRA regimen. What was really interesting also to note of this before I go on to the results was that 52% of patients on this trial had de novo metastatic disease. And that's pretty unusual for any kind of metastatic breast cancer trial. It kind of shows you, though, just how aggressive this disease is, that a lot of patients, they present with de novo metastatic disease. It's also reflecting the global nature of this trial where maybe the screening efforts are a little bit less than maybe in the United States, and more patients are presenting as later stage because to have a metastatic breast cancer trial in the United States with 52% de novo metastatic disease doesn't usually happen. But regardless, the disease characteristics were pretty well matched between the two groups. 54% of the patients were triple positive, or you could say hormone-positive because whether they were PR positive or ER positive and PR negative doesn't really matter in this disease. And so, the interim data cutoff was February of this year, of 2025. So, the follow-up so far has been about 29 months, so the data is still really immature, only 38% mature for progression-free survival interim analysis. But what we saw is that T-DXd plus pertuzumab, it really improved progression-free survival. It had a hazard ratio that was pretty phenomenal at 0.56 with a confidence interval that was pretty narrow of 0.44 to 0.71. So, very highly statistically significant data here. The progression-free survival was consistent across all subgroups. Overall survival, very much immature at this time, but of course, the trend is towards an overall survival benefit for the T-DXd group. The median durable response with T-DXd plus pertuzumab exceeded 3 years. Now, importantly, though, I want to stress this, is grade 3 or above treatment-emergent adverse events occurred in both subgroups pretty equally. But there were 2 deaths in the T-DXd group due to interstitial lung disease. And there was a 12.1% adjudicated drug-induced interstitial lung disease/pneumonitis event rate in the T-DXd group and only 1%, and it was grade 1-2, in the THP group. So, that's really the caveat of this therapy, is we know that a percentage of patients are going to get interstitial lung disease, and that some may have very serious adverse events from it. So, that's always something I keep in the back of my mind when I treat patients with T-DXd. And so, overall, the conclusions of the trial were pretty much a slam dunk. T-DXd plus pertuzumab, it had a highly statistically significant and clinically meaningful improvement in progression-free survival versus the CLEOPATRA regimen. And that was across all subgroups for first-line metastatic HER2-positive breast cancer here. And so, yeah, the data was pretty impressive. Just to go into the overall response rate, because that's always super important as well, you had 85.1% of patients having a confirmed overall RECIST response rate in the T-DXd plus pertuzumab group and a 78.6 in the CLEOPATRA group. The complete CR rate, complete response was 15.1% in the T-DXd group and 8.5 in the CLEOPATRA regimen. And it was really an effective regimen in this group, of course. Dr. Allison Zibelli: So, the investigators say at the end of their abstract that this is the new standard of care. Would you agree with that statement? Dr. Rebecca Shatsky: Yeah, that was a bold statement to make because I would say in the United States, not necessarily at the moment because the quality of life here, you have to think really hard about. Because one thing that's really important about the DESTINY-Breast09 data is that this was very much an international trial, and in many of the countries where patients enrolled on this, they were not able to access T-DXd off trial. And so, for them, this means T-DXd now or potentially never. And so, that is a really big difference whereas internationally, that may mean standard of care. However, in the US, patients have no issues accessing T-DXd in the second- or third-line settings. And right now, it's the standard of care in the second line in the United States, with all patients basically getting this second-line therapy except for some unique patients where they may be doing a PATINA trial regimen, which we saw at San Antonio Breast Cancer in 2024 of the triple-positive patients getting hormonal therapy plus palbociclib, which had a really great durable response. That was super impressive as well. Or there is the patient that the investigator can pick KADCYLA because the patient really wants to preserve their hair or maybe it's more indolent disease. But the quality of life on T-DXd indefinitely in the first-line setting is a big deal because, again, that CLEOPATRA regimen allows patients to drop their chemotherapy component about five to six months in. And with this, you're on a drug that feels very chemo-heavy indefinitely. And so, I think there's a lot more to investigate as far as what we're going to do with this data in the United States because it's a lot to commit a patient in the first-line metastatic setting. These de novo metastatic patients, some of them may be cured, honestly, on the HER2-targeting regimen. That's something we see these days. Dr. Allison Zibelli: So, very interesting trial. I'm sure we'll be talking about this for a long time.  So, let's move on to SERENA-6, which was, I thought, a very interesting trial. This trial took patients with ER positive, advanced breast cancer after six months on an AI (aromatase inhibitor) and a CDK4/6 inhibitor. They did ctDNA every two to three months, and when they saw an ESR1 mutation emerge, they changed half of the patients to camizestrant plus CDK4/6 and kept the other half on the AI plus CDK4/6. Can you talk about that trial a little bit, please? Dr. Rebecca Shatsky: Yeah, so this was a big trial at ASCO25. This was presented as a Plenary Session. So, this was camizestrant plus a CDK4/6 inhibitor, and it could have been any of the three, so palbo, ribo, or abemaciclib in the first-line metastatic hormone-positive population, and patients were on an AI with that. They were, interestingly, tested by ctDNA at baseline to see if they had an ESR1 mutation. So, that was an interesting feature of this trial. But patients had to have already been on their CDK4/6 inhibitor plus AI for at least 6 months to enroll. And then, as you mentioned, they got ctDNA testing every 2 to 3 months. This was also a phase 3, double-blind, international trial. And I do want to highlight again, international here, because that's important when we're considering some of this data in the U.S. because it influences some of the results. So, this was presented by Dr. Nick Turner of the Royal Marsden in the UK. So, just a little bit of background for our listeners on ESR1 mutations and why they're important. This is the most common, basically, acquired resistance mutation to patients being treated with aromatase inhibitors. We know that treatment with aromatase inhibitors can induce this. It makes a conformational change in the estrogen receptor that makes the estrogen receptor constitutively active, which allows the cell to signal despite the influence of the aromatase inhibitor to decrease the estrogen production so that the ligand binding doesn't matter as much as far as the cell signaling and transcription is concerned. And camizestrant, you know, as an oral SERD, just to explain that a little bit too; these are estrogen receptor degraders. The first-in-class of a selective estrogen receptor degrader to make it to market was fulvestrant. And that's really been our standard-of-care estrogen degrader for the past 25 years, almost 25 years. And so, a lot of us are just looking for some of these oral SERDs to replace that. But regardless, they do tend to work in the ESR1-mutated population. And we know that patients on aromatase inhibitors, the estimates of patients developing an ESR1 mutation, depending on which study you look at, somewhere between 30% to 50% overall, patients will develop this mutation with hormone-positive metastatic breast cancer. There is a small percentage of patients that have these at baseline without even treatment of an aromatase inhibitor. The estimates of that are somewhere between 0.5 and up to 5%, depending on the trial you look at and the population. But regardless, there is a chance someone on their CDK4/6 inhibitor plus AI at 6 months' time course could have had an ESR1 mutation at that time. But anyway, so they got this ctDNA every 2 to 3 months, and once they were found to develop an ESR1 mutation, the patients were then switched to the oral SERD. AstraZeneca's version of the oral SERD is camizestrant, 75 mg daily. And then their type of CDK4/6 inhibitor was maintained, so they didn't switch the brand of their CDK4/6 inhibitor, importantly. And that was looked at then for progression-free survival, but these were patients with measurable disease by RECIST version 1.1. And the data cut off here was November of 2024. This was a big trial, you know, and I think that that's influential here because this was 3,256 patients, and that's a lot of patients. So, they were all eligible. And then 315 patients ended up being randomized to switch to camizestrant upon presence of that ESR1 mutation. So, that was 157 patients. And then the other half, so they were randomized 1:1, they continued on their AI without switching to an oral SERD. That was 158 patients. They were matched pretty well. And so, their baseline characteristics, you know, the two subgroups was good. But this was highly statistically significant data. I'm not going to diminish that in any way. Your hazard ratio was 0.44. Highly statistically significant confidence intervals. And you had a median progression-free survival in those that switched to camizestrant of 16 months, and then the non-switchers was 9.2 months. So, the progression-free survival benefit there was also consistent across the subgroups. And so, you had at 12 months, the PFS rate was 60.7% for the non-treatment group and 33.4% in the treatment group. What's interesting, though, is we don't have overall survival data. This is really immature, only 12% mature as far as overall survival. And again, because this was an international trial and patients in other countries right now do not have the access to oral SERDs that the United States does, the crossover rate, they were not allowed to crossover, and so, a very few patients, when we look at progression-free survival 2 and ultimately overall survival, were able to access an oral SERD in the off-trial here and in the non-treatment group. And so, that's really important as far as we look at these results. Adverse events were pretty minimal. These are very safe drugs, camizestrant and all the other oral SERDs. They have some mild toxicities. Camizestrant is known for something weird, which is called photopsia, which is some flashing lights in the periphery of the eye, but it doesn't seem to have any serious clinical significance that we know of. It has a little bit of bradycardia, but it's otherwise really well tolerated. You know, I hate to say that because that's very subjective, right? I'm not the one taking the drug. But it doesn't have any serious adverse events that would cause discontinuation. And that's really what we saw in the trial. The discontinuation rates were really low. But overall, I mean, this was a positive trial. SERENA-6 showed that switching to camizestrant at the first sign of an ESR1 mutation on CDK4/6 inhibitor plus AI improved progression-free survival. That's all we can really say from it right now. Dr. Allison Zibelli: So, let's move on to ASCENT-04, which was a bit more straightforward. Sacituzumab govitecan plus pembrolizumab versus chemotherapy plus pembrolizumab in PD-L1-positive, triple-negative breast cancer. Could you talk about that study? Dr. Rebecca Shatsky: Yeah, so this was also presented by the lovely Sara Tolaney from Dana-Farber. And this study made me really excited. And maybe that's because I'm a triple-negative breast cancer person. I mean, not to say that I don't treat hundreds of patients with hormone- positive, but our unmet needs in triple negative are huge because this is a disease where you have got to throw your best available therapy at it as soon as you can to improve survival because survival is so poor in this disease. The average survival with metastatic triple-negative breast cancer in the United States is still 13-18 months, and that's terrible. And so, for full disclosure, I did have this trial open at my site. I was one of the site PIs. I'm not the global PI of the study, obviously. So, what this study was was for patients who had had at least a progression-free survival of 6 months after their curative intent therapy or de novo metastatic disease. They were PD-L1 positive as assessed by the Dako 22C3 assay of greater than or equal to a CPS score of 10. So, that's what the KEYNOTE-355 trial was based on as well. So, standard definition of PD-L1 positive in breast cancer here. And basically, these patients were randomized 1:1 to either their sacituzumab govitecan plus pembrolizumab, day 1 they got both therapies, and then day 8 just the saci, as is standard for sacituzumab. And then the other group got the KEYNOTE-355 regimen. So, that is pembrolizumab with – your options are carbogem there, paclitaxel or nab-paclitaxel. And it's up to investigator's decision which upon those they decided. They followed these patients for disease progression or unacceptable toxicity. It was really an impressive trial in my opinion because we know already that this didn't just improve progression-free survival, because survival is so poor in this disease, of course, we know that it improved overall survival. It's trending towards that very much, and I think that's going to be shown immediately. And then the objective response rates were better, which is key in this disease because in the first-line setting, you've got a lot of people who, especially your relapsed TNBC that don't respond to anything. And you lose a ton of patients even in the first-line setting in this disease. And so, this was 222 patients to chemotherapy and pembro and 221 to sacituzumab plus pembro. Median follow-up has only been 14 months, so it's still super early here. Hazard ratio so far of progression-free survival is 0.65, highly statistically significant, narrow confidence intervals. And so, the median duration of response here for the saci group was 16.5 months versus 9.2 months. So, you're getting a 7-month progression-free survival benefit here, which in triple negative is pretty fantastic. I mean, this reminds me of when we saw the ASCENT data originally come out for sacituzumab, and we were all just so happy that we had this tool now that doubled progression-free and overall survival and made such a difference in this really horrible disease where patients do poorly. So, OS is technically immature here, but it's really trending very heavily towards improvement in overall survival. Importantly, the treatment-related adverse events in this, I mean, we know sacituzumab causes neutropenia, people who are experienced with this drug know how to manage it at this point. There wasn't any really unexpected treatment-related adverse events. You get some people with sacituzumab who have diarrhea. It's usually pretty manageable with some Imodium. So, it was cytopenias predominantly in this disease in this population that were highlighted as far as adverse events. But I'm going to be honest, like I was surprised that this wasn't the plenary over the SERENA-6 data because this, in my mind, there we have a practice-changing trial. I will immediately be trying to use this in my PD-L1 population because, to be honest, as a triple-negative breast cancer clinical specialist, when I get a patient with metastatic triple-negative breast cancer who's PD-L1 positive, I think, "Oh, thank God," because we know that part of the disease just does better in general. But now I have something that really could give them a durable response for much longer than I ever thought possible when I started really heavily treating this disease. And so, this was immediately practice-changing for me. Dr. Allison Zibelli: I think that it's pretty clear that this is at least an option, if not the option, for this group of patients. Dr. Rebecca Shatsky: Yeah, the duration of responses here was – it's just really important because, I mean, I do think this will make people live longer. Dr. Allison Zibelli: So, moving on to the final study that we're going to discuss today, neoCARHP (LBA500), which was neoadjuvant taxane plus trastuzumab, pertuzumab, plus or minus carbo(platin) in HER2-positive early breast cancer. I think this is a study a lot of us have been waiting for. What was the design and the results of this trial? Dr. Rebecca Shatsky: I was really excited about this as well because I'm one of those people that was waiting for this. This is a Chinese trial, so that is something to take note of. It wasn't an international trial, but it was a de-escalation trial which had become really popular in HER2-positive therapy because we know that we're overtreating HER2-positive breast cancer in a lot of patients. A lot of patients we're throwing the kitchen sink at it when maybe that is not necessary, and we can really de-escalate and try to personalize therapy a little bit better because these patients tend to do well. So, the standard of care, of course, in HER2-positive curative intent breast cancer with tumors that are greater than 2 cm is to give them the TCHP regimen, which is docetaxel, carboplatin, trastuzumab, and pertuzumab. And that was sort of established by several trials in the NeoSphere trial, and now it's been repeated in a lot of different studies as well. And so, that's really the standard of care that most people in the United States use for HER2-positive curative intent breast cancer. This was a trial to de-escalate the carboplatin, which I was super excited about because many of us who treat this disease a lot think carbo is the least important part of the therapy you're giving there. We don't really know that it's necessary. We've just been doing it for a long time, and we know that it adds a significant amount of toxicity. It causes thrombocytopenia, it causes severe nausea, really bad cytopenias that can be difficult in the last few cycles of this to manage. So, this trial was created. It randomized patients one to one with stage 2 and 3 HER2-positive breast cancer to either get THP, a taxane, pertuzumab, trastuzumab, similar to the what we do in first-line metastatic HER2-positive versus the whole TCHP with a carboplatin AUC of 6, which is what's pretty standard. And it was a non-inferiority trial, so important there. It wasn't to establish superiority of this regimen, which none of us, I think, were looking for it to. And it was a modified intent-to-treat population. And so, all patients got at least one cycle of this to be assessed as a standard for an intent-to-treat trial. And so, they assumed a pCR rate of about 62.8% for both groups. And, of course, it included both HER2-positive triple positives and ER negatives, which are, you know, a bit different diseases, to be honest, but we all kind of categorize them and treat them the same. And so, this trial was powered appropriately to detect a non-inferiority difference. And so, we had about 380 patients treated on both arms, and there was an absolute difference of only 1.8% of those treated with carbo versus those without. Which was fantastic because you really realized that de-escalation here may be something we can really do. And so, the patients who got, of course, the taxane regimen had fewer adverse events. They had way fewer grade 3 and 4 adverse events than the THP group. No treatment-associated deaths occur, which is pretty standard for- this is a pretty safe regimen, but it causes a lot of hospitalizations due to diarrhea, due to cytopenias, and neutropenic fever, of course. And so, I thought that this was something that I could potentially enact, you know, and be practice-changing. It's hard to say that when it's a trial that was only done in China, so it's not necessarily the United States population always. But I think for patients moving forward, especially those with, say, a 2.5 cm tumor, you know, node negative, those, I'd feel pretty comfortable not giving them the carboplatin here. Notes that I want to make about this population is that the majority were stage 2 and not stage 3. They weren't necessarily your inflammatory HER2-positive breast cancer patients. And that the taxane that was utilized in the trial is a little different than what we use in the United States. The patients were allowed to get nab-paclitaxel, which we don't have FDA approval for in the first-line curative intent setting for HER2-positive breast cancer in the United States. So, a lot of them got abraxane, and then they also got paclitaxel. We tend to use docetaxel every 3 weeks in the United States. So, just to point out that difference. We don't really know if that's important or not, but it's just a little bit different to the population we standardly treat. Dr. Allison Zibelli: So, are there patients that you would still give TCHP to? Dr. Rebecca Shatsky: Yeah, great question. I've been asked that a lot in the past like week since ASCO. I'd say in my inflammatory breast cancer patients, that's a group I do tend to sometimes throw the kitchen sink at. Now, I don't actually use AC in those because I know that that was the concern, but I think the TRAIN-2 trial really showed us you don't need to use Adriamycin in HER2-positive disease unless it's like refractory. So, I don't know that I would throw this on my stage 3C or inflammatory breast cancer patients yet because the majority of this were not stage 3. So, in your really highly lymph node positive patients, I'm a little bit hesitant to de-escalate them from the start. This is more of a like, if there's serious toxicity concerns, dropping carbo is absolutely fine here. Dr. Allison Zibelli: All right, great.  Thank you, Dr. Shatsky, for sharing your valuable insights with us on the ASCO Daily News Podcast today. Dr. Rebecca Shatsky: Thanks so much, Dr. Zibelli and ASCO Daily News. I really want to thank you for inviting me to talk about this today. It was really fun, and I hope you find my opinions on some of this valuable. And so, I just want to thank everybody and my listeners as well. Dr. Allison Zibelli: And thank you to our listeners for joining us today. You'll find the links to all the abstracts discussed today in the transcript of this episode. Finally, if you like this podcast and you learn things from it, please take a moment to rate, review, and describe because it helps other people find us wherever you get your podcasts. Thank you again. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers Dr. Allison Zibelli Dr. Rebecca Shatsky @Dr_RShatsky Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn   Disclosures: Dr. Allison Zibelli: No relationships to disclose Dr. Rebecca Shatsky: Consulting or Advisory Role: Stemline, Astra Zeneca, Endeavor BioMedicines, Lilly, Novartis, TEMPUS, Guardant Health, Daiichi Sankyo/Astra Zeneca, Pfizer Research Funding (Inst.): OBI Pharma, Astra Zeneca, Greenwich LifeSciences, Briacell, Gilead, OnKure, QuantumLeap Health, Stemline Therapeutics, Regor Therapeutics, Greenwich LifeSciences, Alterome Therapeutics  

Dhineli Perera talks to pharmacists Amy Legg and Tony Lai about their paper on the safe and effective use of vancomycin. They discuss the evolution of vancomycin therapeutic drug monitoring, including trough concentrations, and demystify AUC monitoring. They cover current recommendations, including targets for drug efficacy and safety, and priority patient groups. Read the full article by Amy, Tony, and their co-authors, in Australian Prescriber.

Stéphane Bern dévoile l'histoire d'un ouvrage pas comme les autres, un manuscrit rare qui se dévoile lui-même au musée Condé du Château de Chantilly : "Les Très Riches Heures du duc de Berry", considéré comme la « Joconde » des manuscrits, le « roi des livres d'heures » qui, en plus d'être un livre de prières, est aussi un livre… d'Histoire ! Ce manuscrit a-t-il participé à la légende autour du duc de Berry ? En quoi "Les Très Riches Heures du Duc de Berry" est-il l'une des œuvres fondatrices de l'histoire de l'art occidental ? Comment expliquer l'engouement qui existe toujours aujourd'hui autour de cet ouvrage hors du commun ? Pour en parler, Stéphane Bern reçoit Mathieu Deldicque, conservateur en chef du patrimoine et directeur du musée Condé au Château de Chantilly qui propose l'exposition "Les Très Riches Heures du Duc de Berry" jusqu'au 5 octobre 2025. Au Cœur de l'Histoire est réalisée par Loïc Vimard. Rédaction en chef : Benjamin Delsol. Auteure du récit : Marine Guiffray. Journaliste : Clara Leger. Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Stéphane Bern dévoile l'histoire d'un ouvrage pas comme les autres, un manuscrit rare qui se dévoile lui-même au musée Condé du Château de Chantilly : "Les Très Riches Heures du duc de Berry", considéré comme la « Joconde » des manuscrits, le « roi des livres d'heures » qui, en plus d'être un livre de prières, est aussi un livre… d'Histoire ! Ce manuscrit a-t-il participé à la légende autour du duc de Berry ? En quoi "Les Très Riches Heures du Duc de Berry" est-il l'une des œuvres fondatrices de l'histoire de l'art occidental ? Comment expliquer l'engouement qui existe toujours aujourd'hui autour de cet ouvrage hors du commun ? Pour en parler, Stéphane Bern reçoit Mathieu Deldicque, conservateur en chef du patrimoine et directeur du musée Condé au Château de Chantilly qui propose l'exposition "Les Très Riches Heures du Duc de Berry" jusqu'au 5 octobre 2025. Au Cœur de l'Histoire est réalisée par Loïc Vimard. Rédaction en chef : Benjamin Delsol. Auteure du récit : Marine Guiffray. Journaliste : Clara Leger. Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Stéphane Bern raconte, à la veille de la visite d'État du président Macron sur le rocher, la crise diplomatique qui, en 1962, a opposé le Prince Rainier III au général De Gaulle dans un bras de fer qui a failli bien remettre en cause les liens historiques entre la France et la principauté… À quand remontent les toutes premières tensions qui opposent la France à Monaco ? Quelles ont été les conséquences de ce conflit ? Pourquoi la principauté de Monaco n'est-elle jamais devenue totalement indépendante ? Pour en parler, Stéphane Bern reçoit Pierre Fabry, historien et auteur de "Histoire de Monaco" (Passés Composés). Au Cœur de l'Histoire est réalisée par Guillaume Vassseau. Rédaction en chef : Benjamin Delsol. Auteur du récit : Eloi Audoin-Rouzeau. Journaliste : Clara Leger.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Stéphane Bern raconte, à la veille de la visite d'État du président Macron sur le rocher, la crise diplomatique qui, en 1962, a opposé le Prince Rainier III au général De Gaulle dans un bras de fer qui a failli bien remettre en cause les liens historiques entre la France et la principauté… À quand remontent les toutes premières tensions qui opposent la France à Monaco ? Quelles ont été les conséquences de ce conflit ? Pourquoi la principauté de Monaco n'est-elle jamais devenue totalement indépendante ? Pour en parler, Stéphane Bern reçoit Pierre Fabry, historien et auteur de "Histoire de Monaco" (Passés Composés). Au Cœur de l'Histoire est réalisée par Guillaume Vassseau. Rédaction en chef : Benjamin Delsol. Auteur du récit : Eloi Audoin-Rouzeau. Journaliste : Clara Leger.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Virginie Girod vous transporte Au Cœur de l'Histoire, à la découverte des poèmes de Phillis Wheatley (1753-1784). Arrachée à ses terres natales et réduite en esclavage dans l'Amérique coloniale du XVIIIe siècle, Phillis Wheatley parvient à sortir de sa condition et marque bientôt l'Histoire de la littérature afro-américaine, devenant une poétesse majeure. Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Toute cette semaine, Au Cœur de l'Histoire spéciale "Ils ont choisi la France !" Ou les destins de personnages qui se sont fait un – grand – nom dans notre pays. Pour le 3e épisode, Stéphane Bern raconte Fryderyk Franciszek Chopin, dit Frédéric Chopin, jeune pianiste célèbre en son pays qui a décidé de quitter sa Pologne natale pour Vienne avant tenter sa chance dans l'autre capitale musicale de l'Europe : Paris... Et bien lui en a pris ! Pourquoi la musique de Chopin parle-t-elle à tout le monde ? Comment a-t-il inventé le piano moderne ? Comment sa musique a-t-elle traversé les siècles sans perdre de sa splendeur ? Pour en parler, Stéphane Bern reçoit Jean-Yves Clément, écrivain, auteur de "Chopin et Liszt, la magnificence des contraires" (Passés Composés, collection Alpha). Au Cœur de l'Histoire est réalisée par Pierre Cazalot. Rédaction en chef : Benjamin Delsol. Auteur du récit : Pïerre-Vincent Letourneau. Journaliste : Clara Leger. Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Toute cette semaine, Au Cœur de l'Histoire spéciale "Ils ont choisi la France !" Ou les destins de personnages qui se sont fait un – grand – nom dans notre pays. Pour le 3e épisode, Stéphane Bern raconte Fryderyk Franciszek Chopin, dit Frédéric Chopin, jeune pianiste célèbre en son pays qui a décidé de quitter sa Pologne natale pour Vienne avant tenter sa chance dans l'autre capitale musicale de l'Europe : Paris... Et bien lui en a pris ! Pourquoi la musique de Chopin parle-t-elle à tout le monde ? Comment a-t-il inventé le piano moderne ? Comment sa musique a-t-elle traversé les siècles sans perdre de sa splendeur ? Pour en parler, Stéphane Bern reçoit Jean-Yves Clément, écrivain, auteur de "Chopin et Liszt, la magnificence des contraires" (Passés Composés, collection Alpha). Au Cœur de l'Histoire est réalisée par Pierre Cazalot. Rédaction en chef : Benjamin Delsol. Auteur du récit : Pïerre-Vincent Letourneau. Journaliste : Clara Leger. Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Aujourd'hui et demain, Au Cœur de l'Histoire nous offre un dyptique spécial consacré à un couple royal : Marie de Médicis et Henri IV. Pour le premier épisode, avant de découvrir le destin du roi assassiné, Stéphane Bern raconte celui de la richissime héritière des grands ducs de Toscane devenue reine, qui fut couronnée en la basilique Saint-Denis, le 13 mai 1610, il y a 415 ans jour pour jour, juste avant ce terrible événement, justement… Quels étaient les enjeux d'une telle cérémonie ? Quel est le rôle d'une reine ? Pourquoi Marie de Médicis souffre-t-elle, aujourd'hui encore, d'une image négative ? Pour en parler, Stéphane Bern reçoit Jean-Christian Petitfils, historien, spécialiste des rois Bourbon, et auteur de la biographie ""Henri IV"" (Perrin). Au Coeur de l'Histoire est réalisée par Pierre Cazalot. Rédaction en chef : Benjamin Delsol. Auteur du récit : Pierre-Vincent Letourneau. Journaliste : Armelle Thiberge. "Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Aujourd'hui et demain, Au Cœur de l'Histoire nous offre un dyptique spécial consacré à un couple royal : Marie de Médicis et Henri IV. Pour le premier épisode, avant de découvrir le destin du roi assassiné, Stéphane Bern raconte celui de la richissime héritière des grands ducs de Toscane devenue reine, qui fut couronnée en la basilique Saint-Denis, le 13 mai 1610, il y a 415 ans jour pour jour, juste avant ce terrible événement, justement… Quels étaient les enjeux d'une telle cérémonie ? Quel est le rôle d'une reine ? Pourquoi Marie de Médicis souffre-t-elle, aujourd'hui encore, d'une image négative ? Pour en parler, Stéphane Bern reçoit Jean-Christian Petitfils, historien, spécialiste des rois Bourbon, et auteur de la biographie ""Henri IV"" (Perrin). Au Coeur de l'Histoire est réalisée par Pierre Cazalot. Rédaction en chef : Benjamin Delsol. Auteur du récit : Pierre-Vincent Letourneau. Journaliste : Armelle Thiberge. "Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Stéphane Bern raconte, 75 ans, jour pour jour, après son discours entré dans l'Histoire qui donna le coup d'envoi de la construction européenne, le destin de Robert Schuman, homme politique de premier plan, premier artisan de la réconciliation franco-allemande devenu le “père de l'Europe”… Quelle était sa définition de la politique ? Comment la Communauté européenne du charbon et de l'acier, dont Robert Schuman est à l'initiative, a-t-elle abouti à notre Union européenne ? Quelles traces reste-t-il encore de Schuman en Europe aujourd'hui ? Pour en parler, Stéphane Bern reçoit Jean-Dominique Giuliani, Président de la Fondation Robert Schuman. Au Cœur de l'Histoire est réalisée par Guillaume Vasseau. Rédaction en chef : Benjamin Delsol. Auteur du récit : Jean-Pierre Vrignaud. Journaliste : Clara Leger.Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

Stéphane Bern raconte le destin tourmenté de celle qui fut héroïne de sa propre vie, entre création, ennui et folie, la véritable histoire d'Adèle H., pour reprendre le titre du film de François Truffaut, la fille de Victor Hugo. Comment Adèle Hugo a-t-elle repris son destin en main pour retrouver sa liberté ? Quelles traces a-t-elle laissées avec ses écrits ? Pourquoi a-t-elle toujours été réduite à sa folie ? Pour en parler, Stéphane Bern reçoit Laura El Makki, journaliste et auteure de "Adèle Hugo, ses écrits, son histoire" (Seghers). Au Cœur de l'Histoire est réalisée par Loïc Vimard. Rédaction en chef : Benjamin Delsol. Auteur du récit : Jean-Christophe Piot. Journaliste : Clara Leger. Distribué par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.